Avidity Biosciences, Inc.'s innovative AOC platform and promising clinical programs make it a high-risk, high-reward ...

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received a consensus rating of “Buy” from the thirteen research ...

Cibc World Markets Corp bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) during the fourth quarter, ...

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy recommendation. Analyst Price Forecast Suggests 113.85% Upside As of March 5, 2025, ...

Highlights,Swiss National Bank expanded its holdings in Avidity Biosciences Inc. during the fourth quarter.,Multiple ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on ...

SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago.

SAN DIEGO, March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...